Cracking the moody brain: Lifting the mood with ketamine (original) (raw)

Nature Medicine volume 16, pages 1384–1385 (2010)Cite this article

Subjects

Bench to Bedside

Major depression is one of the most disabling and costly medical illnesses worldwide. Despite the large public health burden, the pace of therapeutic discovery for depression has markedly lagged behind other areas of medicine. Current treatments for depression target mostly components of the serotonin or norepinephrine neurochemical systems and are limited in efficacy, showing also a delayed onset of therapeutic benefit of at least two to four weeks. In contrast, studies showing a rapid-onset antidepressant effect for the anesthetic agent ketamine—a glutamate _N_-methyl-D-aspartate (NMDA) receptor antagonist—even in people with treatment-resistant depression (TRD), have engendered a new wave of clinical and basic science research focused on the glutamate system and the NMDA receptor complex in mechanisms of depression and its treatment.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Figure 1: The rapid-acting antidepressant effects of ketamine and the potential role of synaptogenic and neurotrophic mechanisms in depression.

References

  1. Trullas, R. & Skolnick, P. Eur. J. Pharmacol. 185, 1–10 (1990).
    Article CAS Google Scholar
  2. Skolnick, P. et al. Pharmacopsychiatry 29, 23–26 (1996).
    Article CAS Google Scholar
  3. Maeng, S. et al. Biol. Psychiatry 63, 349–352 (2008).
    Article CAS Google Scholar
  4. Li, N. et al. Science 329, 959–964 (2010).
    Article CAS Google Scholar
  5. Berman, R.M. et al. Biol. Psychiatry 47, 351–354 (2000).
    Article CAS Google Scholar
  6. Zarate, C.A. Jr. et al. Arch. Gen. Psychiatry 63, 856–864 (2006).
    Article CAS Google Scholar
  7. Mathew, S.J. et al. Int. J. Neuropsychopharmacol. 13, 71–82 (2010).
    Article CAS Google Scholar
  8. aan het Rot, M. et al. Biol. Psychiatry 67, 139–145 (2010).
    Article CAS Google Scholar
  9. Preskorn, S.H. et al. J. Clin. Psychopharmacol. 28, 631–637 (2008).
    Article CAS Google Scholar
  10. Olney, J.W., Labruyere, J. & Price, M.T. Science 244, 1360–1362 (1989).
    Article CAS Google Scholar
  11. Perry, E.B. Jr. et al. Psychopharmacology (Berl.) 192, 253–260 (2007).
    Article CAS Google Scholar
  12. Price, R.B., Nock, M.K., Charney, D.S. & Mathew, S.J. Biol. Psychiatry 66, 522–526 (2009).
    Article CAS Google Scholar

Download references

Author information

Authors and Affiliations

  1. James W. Murrough is in the Mood and Anxiety Disorders Program, Mount Sinai School of Medicine, New York, New York, USA.,
    James W Murrough
  2. Dennis S. Charney is at the Office of the Dean, Mount Sinai School of Medicine, New York, New York, USA.,
    Dennis S Charney

Authors

  1. James W Murrough
    You can also search for this author inPubMed Google Scholar
  2. Dennis S Charney
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toJames W Murrough.

Ethics declarations

Competing interests

D.S.C. and Mount Sinai School of Medicine have been named on a use patent of ketamine for the treatment of depression. If ketamine were shown to be effective in the treatment of depression and approved by the US Food and Drug Administration for this indication, D.S.C. and Mount Sinai School of Medicine could benefit financially.

Rights and permissions

About this article

Cite this article

Murrough, J., Charney, D. Cracking the moody brain: Lifting the mood with ketamine.Nat Med 16, 1384–1385 (2010). https://doi.org/10.1038/nm1210-1384

Download citation

This article is cited by